AGEN1884 Plus AGEN2034 Combined With Cisplatin-Gemcitabine for Muscle-Invasive Bladder Cancer

NCT ID: NCT04430036

Last Updated: 2024-04-04

Basic Information

• Recruitment Status: TERMINATED
• Clinical Phase: PHASE2
• Total Enrollment: 4 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2020-10-14
• Study Completion Date: 2022-03-14

Brief Summary

This is a phase II trial to evaluate the tolerability, efficacy, and immune outcomes of AGEN1884 plus AGEN2034 concurrent with cisplatin and gemcitabine in the neoadjuvant treatment of muscle-invasive, non-metastatic bladder cancer prior to radical cystectomy.

Detailed Description

We will begin with an initial safety run-in to establish the safety of the combination prior to expansion to the full planned phase II. The overall phase II will be an open-label, single arm study in two stages to evaluate the efficacy of the combination in pathologic downstaging of MIBC. Patients will receive four 21-day cycles of neoadjuvant therapy consisting of cisplatin and gemcitabine plus AGEN2034 in all 4 cycles and AGEN1884 in cycles 1 and 3. Patients will proceed to radical cystectomy within 10 weeks after the final dose of this therapy. The primary endpoint of pathologic tumor downstaging will be assessed at the time of cystectomy.

Conditions

Urinary Bladder Neoplasms

Study Design

• Allocation Method: NA
• Intervention Model: SINGLE_GROUP
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

Cisplatin, Gemcitabine plus human monoclonal antibodies

The safety run-in of the study will first enroll three patients who will begin treatment with cisplatin and gemcitabine plus AGEN2034 and AGEN1884 as outlined in the treatment plan. These first 3 patients will be assessed for DLTs and there will be a pause in enrollment until all three complete the DLT period. If there are no DLTs in the first 3 patients, we will proceed to further accrual to stage I of phase II. If there is 1 DLT in the initial 3 patients, we will enroll 3 additional patients to the safety run-in. If \> 2 DLTs are experienced in the initial 3 patients, the study will be terminated, otherwise additional subjects will be enrolled into the phase ll first stage and reassessed after 2 cycles of therapy and proceed to planned surgery. If criteria are met to continue to the second stage of the Phase II portion of the study, additional patients will be enrolled for an anticipated total of 36 evaluable patients. Patients will be treated and endpoints evaluated.

Group Type: EXPERIMENTAL

AGEN1884

Intervention Type: DRUG

A fully human monoclonal Anti-PD-1 Antibody

AGEN2034

Intervention Type: DRUG

A fully human monoclonal Anti-PD-1 Antibody

Cisplatin

Intervention Type: DRUG

Alkylating antineoplastic agent

Gemcitabine

Intervention Type: DRUG

Antimetabolite antineoplastic agent

Interventions

AGEN1884

A fully human monoclonal Anti-PD-1 Antibody

Intervention Type: DRUG

AGEN2034

A fully human monoclonal Anti-PD-1 Antibody

Intervention Type: DRUG

Cisplatin

Alkylating antineoplastic agent

Intervention Type: DRUG

Gemcitabine

Antimetabolite antineoplastic agent

Intervention Type: DRUG

Other Intervention Names

anti-CTLA-4 antibody; Anti-PD-1; Gemzar, Platinol® and Platinol®-AQ; Gebina, Gemalata, Gembin, Gembine, Gembio, Gemcel, Gemcetin

Eligibility Criteria

Inclusion Criteria

1. Diagnosis of muscle-invasive, non-metastatic urothelial carcinoma of the bladder, cT2-4, N0-1, M0

2. Eligible to receive cisplatin-based chemotherapy, with eligibility defined as meeting all of the following criteria:

1. Eastern Cooperative Oncology Group performance status of ¬0-1

2. Creatinine clearance (CrCl) of >50 mL/min, as measured by 24-hour urine collection or estimated by the CKD-EPI equation. Patients with CrCl between 50 - 60 mL/min are eligible for the study but will receive split dose cisplatin

3. Grade < 2 hearing loss

4. Grade < 2 peripheral neuropathy

5. New York Heart Association Class < III heart failure

3. Eligible to receive gemcitabine as dosed here

4. Patients must have organ and marrow function meeting the criteria below:

Absolute neutrophil count > 2,000/mcL Hemoglobin > 9.0 mg/mL Platelets > 100,000/mcL Total bilirubin within normal limits or known to be elevated due to a benign conjugation defect such as Gilbert's syndrome, as evidenced by normal conjugated bilirubin level AST/ALT < 3X institutional normal limits Creatinine clearance (CrCl) > 50 mL/min/1.73m2, as measured with 24 hr urine collection or estimated by CKD-EPI, whichever is greater

5. Signed, written informed consents to allow transfer of tumor tissue and production of peptides and to receive experimental treatment and monitoring if agreeable, or monitoring without experimental treatment otherwise

6. Age ≥18 years

7. Available fresh tissue from surgical excision. If fresh tissue is not available, archival tissue may be used.

8. Female subjects of childbearing potential must have a negative serum pregnancy test at screening (within 72 hours of first dose of study medication). Non-childbearing potential (other than by medical reasons) is defined as 1 of the following:

1. ≥ 45 years of age and amenorrheic for >1 year by self-report.

2. Amenorrheic for >2 years without a hysterectomy and oophorectomy, and follicle-stimulating hormone value in the postmenopausal range upon pretrial (screening) evaluation.

3. Status post-hysterectomy, -oophorectomy, or -tubal ligation. If of childbearing potential, female subjects must be willing to use adequate birth control during the study, starting with the screening visit through 120 days after the last dose of study therapy.

Male subjects with a female partner(s) of childbearing potential must agree to use a condom throughout the trial, starting with the screening visit through 120 days after the last dose of study therapy. Males with pregnant partners must agree to use a condom; no additional method of contraception is required for the pregnant partner.

Note: Abstinence is acceptable for both female and male subjects if this is the subject's established and preferred contraception method.

Exclusion Criteria

1. Subjects must not have previously received a checkpoint inhibitor ie, anti-PD-1, anti-PD L1, or anti CTLA-4 antibody.

2. Subjects must not have previously received anticancer medications or investigational drugs for the disease under study within the following windows:

a. ≤ 28 days for prior monoclonal antibody used for anticancer therapy, with the exception of denosumab b. ≤ 7 days for immunosuppressive treatment for any reason, with the following exceptions: i. Physiologic steroid replacement for adrenal insufficiency (e.g., <10 mg prednisone per day) is permitted.

ii. Use of inhaled or topical corticosteroid for radiographic procedures is permitted.

c. Systemic corticosteroids < 7 days are not allowed except as defined above. d. ≤ 28 days before first dose of study drug for all other investigational study drugs or devices

3. Has persisting toxicity related to prior therapy of National Cancer Institute Common Terminology Criteria for Adverse Events version 5.0 (NCI-CTCAE) Grade >1 severity.

Note: Sensory neuropathy or alopecia of Grade ≤2 is acceptable.

4. Has known severe hypersensitivity reactions to fully human monoclonal antibodies (NCI-CTCAE Version 5.0 Grade ≥3), any history of anaphylaxis, or uncontrolled asthma.

5. Active or history of any autoimmune disease (subjects with diabetes type 1, vitiligo, psoriasis, hypo- or hyperthyroid disease not requiring immunosuppressive treatment are eligible). Patients with a history of inflammatory bowel disease (including Crohn's disease and ulcerative colitis) and autoimmune disorders such as rheumatoid arthritis, systemic progressive sclerosis [scleroderma], Systemic Lupus Erythematosus or autoimmune vasculitis [e.g., Wegener's Granulomatosis] are excluded from this study.

6. Any condition requiring systemic treatment with corticosteroids (>10mg daily prednisone equivalents) or other immunosuppressive medications within 14 days prior to first dose of study drug. Inhaled steroids and adrenal replacement steroids doses >10mg daily prednisone equivalents are permitted in the absence of active autoimmune disease.

7. Uncontrolled intercurrent illness, including but not limited to uncontrolled infection, interstitial lung disease or active, non-infectious pneumonitis, symptomatic congestive heart failure, unstable angina pectoris, uncontrolled cardiac arrhythmia, or social situations that would limit compliance with study requirements in the opinion of the treating investigator or medical monitor.

8. History of intolerance or allergic reactions attributed to compounds of similar chemical or biologic composition to AGEN1884 or AGEN2034.

9. Women who are pregnant or breastfeeding.

10. Receipt of a live vaccine within 30 days prior to the first dose of study drug.

11. Inability to adhere to the protocol

• Minimum Eligible Age: 18 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

The University of Texas Health Science Center at San Antonio

OTHER

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Chethan Ramamurthy, MD

Role: PRINCIPAL_INVESTIGATOR

University of Texas Health Science Center San Antonio

Locations

Mays Cancer Center

San Antonio, Texas, United States

Countries

United States

Provided Documents

Document Type: Study Protocol and Statistical Analysis Plan

View Document

Other Identifiers

HSC20200027H

Identifier Type: OTHER

Identifier Source: secondary_id

CTMS 19-0193

Identifier Type: -

Identifier Source: org_study_id